Authors
Ana I Boeriu, Tianjie Gu, Brian Fulton-Howard, Esteban M Lucero, Paras Garg, Andrew J Sharp, Jonathan A Shortt, Chris R Gignoux, Farid Rajabli, Anthony J Griswold, Kristine Yaffe, Shea J Andrews, HABS‐HD Study Team
Published in
Alzheimer's & dementia : the journal of the Alzheimer's Association. Volume 22. Issue 11.
Abstract
Apolipoprotein E (APOE) *ε4 is the strongest genetic risk factor for Alzheimer's disease (AD), yet its effect varies across ancestral populations. As plasma biomarkers increasingly inform AD diagnosis, failure to account for both APOE genotype and genetic ancestry could lead to diagnostic misclassification.
In 2,733 participants from the Health and Aging Brain Study-Health Disparities (HABS-HD), we evaluated whether genetically-inferred ancestry modifies APOE associations with AD endophenotypes. Regression models were applied across three frameworks: ancestry-stratified analyses, compositional modeling of global ancestry, and local ancestry analyses at the APOE locus.
APOE ε4+ was associated with higher pTau217 and pTau181, lower Aβ42/Aβ40, and worse global cognition (Clinical Dementia Rating - Sum of Boxes [CDR-SB]), significant within ancestry groups after false discovery rate (FDR) correction. The ε4+ effect on pTau217 was ∼2.5-fold larger in EUR-like than AFR-like participants.
African ancestry attenuates APOE*ε4+ associations with pTau217, highlighting the need to consider both APOE genotype and ancestry in biomarker-based AD evaluations.
PMID:
43058971
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0